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Abstract
Aims/hypothesis Retinol-binding protein 4 (RBP4), origi-
nally known for retinol transport, was recently identified as
an adipokine affecting insulin resistance. The RBP4
−803GA promoter polymorphism influences binding of
hepatic nuclear factor 1α and is associated with type 2
diabetes in case–control studies. We hypothesised that the
RBP4 −803GA polymorphism increases type 2 diabetes
risk at a population-based level. In addition, information on
retinol intake and plasma vitamin A levels enabled us to
explore the possible underlying mechanism.
Methods In the Rotterdam Study, a prospective, population-
based, follow-up study, the −803GA polymorphism was
genotyped. In Cox proportional hazards models, associa-
tions of the −803GA polymorphism and retinol intake with
type 2 diabetes risk were examined. Moreover, the
interaction of the polymorphism with retinol intake on type
2 diabetes risk was assessed. In a subgroup of participants
the association of the polymorphism and vitamin A plasma
levels was investigated.
Results Homozygous carriers of the −803A allele had
increased risk of type 2 diabetes (HR 1.83; 95% CI 1.26–
2.66). Retinol intake was not associated with type 2
diabetes risk and showed no interaction with the RBP4
−803GA polymorphism. Furthermore, there was no signif-
icant association of the polymorphism with plasma vitamin
A levels.
Conclusions/interpretation Our results provide evidence
that homozygosity for the RBP4 −803A allele is associated
with increased risk of type 2 diabetes in the Rotterdam
population. This relationship was not clearly explained
by retinol intake and vitamin A plasma levels. Therefore,
we cannot differentiate between a retinol-dependent or
-independent mechanism of this RBP4 variant.
Keywords Polymorphism.RBP4.Retinol.Type2
diabetes.VitaminA
Abbreviations
HNF1α hepatic nuclear factor 1α
PEPCK phosphoenolpyruvate carboxykinase
RBP4 retinol-binding protein 4
RE retinol equivalent
RXR retinoid acid X receptor
Introduction
Insulin resistance and beta cell failure are major compo-
nents of the pathogenesis of type 2 diabetes [1]. In the past
years, it has become apparent that adipose tissue is an
endocrine organ that secretes adipokines affecting insulin
sensitivity [2]. Recently, retinol-binding protein 4 (RBP4)
was identified as a new adipokine that links glucose uptake
in adipocytes to systemic insulin resistance [3].
Originally, RBP4 was known as the only transport
protein for retinol [4], but Yang et al. [3] demonstrated a
new function, by showing that adipose tissue-specific Glut4
(also known as Slc2a4) knockout mice have increased
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Rotterdam, the Netherlandsserum levels of RBP4. Downregulation of GLUT4 in
adipose tissue is an important feature of insulin resistance
[5]. RBP4 may be an important mechanistic link between
downregulated GLUT4 in adipose tissue and systemic
insulin resistance. This was confirmed in humans as well:
RBP4 levels and the level of insulin resistance were
correlated in people with obesity and impaired glucose
tolerance, and in patients with type 2 diabetes [6].
Moreover, RBP4 correlated with the level of insulin
resistance in normoglycaemic men with a positive family
history of type 2 diabetes, suggesting an underlying genetic
predisposition. [6]
In a Mongolian case–control study, four single nucleo-
tide polymorphisms in the RBP4 gene were associated with
increased risk of type 2 diabetes [7]. The −803GA
polymorphism, located near an hepatic nuclear factor 1α
(HNF1α)-binding motif, affects serum RBP4 levels and
influences transcription efficiency and binding of HNF1α
[7]. So far, the relationship between genetic variants in the
RBP4 gene and type 2 diabetes risk has not been studied
prospectively.
The mechanisms by which RBP4 affects insulin sensi-
tivity are largely unknown. Yang et al. [3] showed that
RBP4 impaired muscle insulin signalling and increased the
levels of phosphoenolpyruvate carboxykinase (PEPCK) in
mouse liver. Whether these effects are based on retinol-
dependent or -independent mechanisms is unclear.
The findings so far suggest that variation in the RBP4
gene is involved in the pathogenesis of type 2 diabetes and
that RBP4 is a candidate gene for type 2 diabetes
susceptibility. In a large prospective population-based
study, we investigated the effect of the RBP4 −803GA
polymorphism on type 2 diabetes risk. In addition, we
assessed the association of retinol intake with risk of type 2
diabetes and its interaction with the RBP4 polymorphism.
Finally, we analysed the effect of the RBP4 polymorphism
on plasma vitamin A levels.
Methods
Study population Details of the Rotterdam Study have been
described previously [8]. In short, the Rotterdam Study is
an ongoing prospective, population-based, cohort study in
7,983 inhabitants of a suburb in Rotterdam, designed to
investigate determinants of chronic diseases in the elderly.
Participants were aged 55 years or older. Baseline exami-
nations were performed from 1990 until 1993. Follow-up
examinations took place in 1993–1994, 1997–1999 and
2002–2004. Continuous surveillance on major disease
outcomes was conducted between these examinations.
Information on vital status was derived from municipal
health authorities. The medical ethics committee of the
Erasmus Medical Center approved the study protocol and
all participants gave their written informed consent.
Diabetes In accordance with the guidelines of the World
Health Organization [9] and the American Diabetes
Association [10], diabetes was diagnosed at fasting plasma
glucose levels ≥7.0 mmol/l and/or a non-fasting plasma
glucose levels ≥11.0 mmol/l and/or treatment with anti-
diabetic medication (oral medication or insulin) and/or a
diagnosis of diabetes as registered by a general practitioner.
At baseline, prevalent cases of diabetes were diagnosed by
a non-fasting or post-load glucose level (after OGTT)
≥11.1 mmol/l and/or treatment with antidiabetic medication
(oral medication or insulin) and the diagnosis diabetes as
registered by a general practitioner.
In the current study, patients diagnosed with type 1
diabetes according to the general practitioners’ records were
excluded. For the present study, baseline data were collected
between 1990 and 1993.
Genotyping DNA material was available for genotyping of
6,571 participants. The −803GA polymorphism (rs3758539)
in the RBP4 gene was genotyped by means of a Taqman
allelic discrimination assay. The assay was designed and
optimised by Applied Biosystems (Foster City, CA, USA;
http://store.appliedbiosystems.com). We genotyped 90 blood
bank samples to test for adequate cloud separation. In the
Rotterdam Study samples, 325 samples were genotyped in
duplo, of which one gave an inconsistent result. To monitor
contamination, 650 blank samples were incorporated on the
plates, of which all gave a blank result. Reactions were
performed on the Taqman Prism 7900HT platform. Geno-
typing was successful in 6,366 participants.
Assessment of dietary and plasma levels of vitamin A Dietary
intake was assessed by means of an extensive, validated
semiquantitative food-frequency questionnaire (SFFQ) [11].
A trained dietitian interviewed the participants. The food
and drink intake from the SFFQ were converted to energy
and nutrient intake according to the Dutch Food Compo-
sition Table [12]. In the current study, we used data on
dietary intake of α-carotene (μg/day) and β-carotene
(μg/day), β-cryptoxanthin (μg/day) and total energy
(kJ/day). Alpha-carotene, β-carotene and β-cryptoxanthin
were converted to retinol equivalents (RE; amount of RE =
[μg retinol] + [μg β-carotene/6] + [μg α-carotene/12] +
[μg β-cryptoxanthin/12] per day). Data on retinol intake
were available for 5,642 participants.
Plasma levels of vitamin Awere measured in a subgroup
of 395 genotyped participants. At the second follow-up
examination, blood samples were drawn after an overnight
fast. Citrate plasma was immediately frozen and stored at
−80°C. Total vitamin A plasma levels (retinol) were deter-
1424 Diabetologia (2008) 51:1423–1428mined by a previously described method [13]. Briefly,
reversed-phase HPLC with UV detection was performed
using an RP C18 Column 100×4.6 mm (Merck Lichrospher
100RP-18e; Merck, Darmstadt, Germany). Vitamin A was
detected at 324 nm. The inter-assay CV was 4.0%.
Statistical methods Analyses were performed with SPSS
software version 12.0.1. Continuous variables are expressed
as means±SEM. Comparisons between groups were
performed with ANOVA and χ
2 testing for normally dis-
tributed continuous and categorical variables, respectively.
Deviation from Hardy–Weinberg equilibrium was assessed
by means of χ
2 testing.
We tested the association of the RBP −803GA polymor-
phism, RE intake and their interaction with type 2 diabetes
risk in Cox proportional hazards models. Participants with
prevalent type 2 diabetes at baseline were excluded from
the analyses, since they may contain selection biases such
as survival bias. For the polymorphism the additive,
dominant or recessive model was chosen based on the
genotypic test and the best-estimated log-likelihood statistic
in univariate Cox proportional hazards regression. For the
interaction analysis an interaction term was created by
entering the product of the −803GA polymorphism and
retinol intake to a model with both independent variables.
All models were adjusted for year of birth and sex.
Additional models were adjusted for BMI.
RE intake was adjusted for energy intake by saving
the standardised residuals of a linear regression model
with RE intake as dependent variable and total energy
intake as independent variable. These standardised resid-
uals represent the remaining variation in RE intake after
correcting for energy intake. These standardised residuals
were entered as an independent variable in subsequent
models.
Results
Baseline characteristics In 6,320 successfully genotyped
people, diabetes status was available. Of these, 658 had
prevalent diabetes at baseline. Individuals whose DNA was
not available or in whom genotyping did not succeed were
5.8 years older and contained 8.5% more women than the
successfully genotyped group. This is explained by the fact
that mostly elderly women in nursing homes did not provide
DNA material for the study at baseline. Still, the genotyped
and non-genotyped groups had similar distributions of BMI,
waist circumference and presence of type 2 diabetes.
Baseline characteristics are shown in Table 1. Incident
cases with type 2 diabetes were significantly younger, had
higher BMI and waist circumference, lower HDL-choles-
terol and more often hypertension than individuals without
type 2 diabetes. As expected, prevalent cases were
significantly older at baseline compared with incident cases
(73.5±0.35 vs 68.1±0.32 years, p<0.001) and people
without diabetes (73.5±0.35 vs 69.0±0.13 years, p<
0.001). They were excluded from further analyses.
The polymorphism was in Hardy–Weinberg equilibrium
in the total population and in individuals without type 2
diabetes (χ
2<1.02, df=2, p>0.33). In the total population,
we found 27.8% heterozygotes for the −803GA polymor-
phism, while 2.8% were homozygous for the A allele.
These percentages were 26.1% and 5.0% and 28.1% and
2.6% in individuals with and without incident type 2
diabetes, respectively; −803AA 5.0% vs 2.6% for incident
cases vs individuals without type 2 diabetes, p=0.01.
The polymorphism was not associated with BMI, total
cholesterol or HDL-cholesterol (data not shown).
Cox proportional HRs for type 2 diabetes of the −803GA
polymorphism Based on the −log-likelihood values and
Table 1 Baseline characteristics of all genotyped participants, participants without diabetes and incident cases of type 2 diabetes
Characteristic All participants
(n=6,320)
Individuals without type
2 diabetes (n=5,080)
Incident cases with type
2 diabetes (n=582)
p value
a
Age (years) 69.3±0.11 69.0±0.13 68.1±0.32 0.02
Men (%) 40.6 40.5 44.0 0.10
BMI (kg/m
2) 26.3±0.05 26.0±0.05 28.0±0.16 <0.001
Waist circumference (cm) 90.5±0.15 89.6±0.16 94.7±0.46 <0.001
Systolic BP (mmHg) 139.4±0.3 138.0±0.3 143.5±0.9 <0.001
Diastolic BP (mmHg) 73.8±0.2 73.7±0.2 75.5±0.5 <0.001
Hypertension (%) 33.6 30.7 46.7 <0.001
Total cholesterol (mmol/l) 6.6±0.02 6.6±0.02 6.6±0.05 0.86
HDL-cholesterol (mmol/l) 1.34±0.005 1.37±0.005 1.25±0.01 <0.001
Current smoker (%) 22.2 22.5 25.5
Former smoker (%) 40.8 42.2 42.1 0.18
Continuous data are expressed as means±SEM
ap value for comparison between incident cases and individuals without diabetes
Diabetologia (2008) 51:1423–1428 1425genotype frequencies in individuals with and without type 2
diabetes, the recessive model of inheritance was the best-
fitting model. Homozygosity for the A allele was associated
with an HR of 1.83 (95% CI 1.26–2.66, p=0.001) for type 2
diabetes compared with the reference group (−803GG/GA)
adjusted for year of birth and sex. Figure 1 shows the effect
of the RBP4 −803GA genotypes on type 2 diabetes-free
survival in our population. The association remained similar
after additional adjustment for BMI (−803AA HR 1.81; 95%
CI 1.25–2.64, p=0.002; Table 2).
RE intake, vitamin A plasma levels, the RBP4 polymor-
phism and risk of type 2 diabetes RE intake corrected for
energy intake was not associated with risk of type 2 diabetes
(HR 1.0; 95% CI 1.0–1.0, p=0.16) and did not interact with
the RBP4 −803GA polymorphism on type 2 diabetes risk
(HR 1.0; 95% CI 0.99–1.00, p for interaction=0.35).
Vitamin A plasma level measurements were available in a
subgroup of 395 genotyped participants. We did not observe
significant differences between individuals with and without
vitamin A plasma measurements with regards to BMI, waist
circumference, sex and type 2 diabetes status. Individuals with
measured vitamin A plasma levels were on average 4.3 years
younger than those without vitamin A plasma measurements
(65.4±0.34 vs 69.7±0.12 years, p<0.001), which is explained
by the fact that they survived and participated until the
second follow-up measurement. In this subgroup, the RBP4
polymorphism was not significantly associated with vitamin
A plasma levels (Table 3).
Discussion
RBP4 is a recently discovered adipokine that is thought to
link adipocyte glucose metabolism to systemic insulin
resistance [3]. In the present study, we demonstrated that
homozygosity for a promoter variant in the RBP4 gene was
associated with increased risk of type 2 diabetes at a
population-based level. Vitamin A intake was not associat-
ed with type 2 diabetes and did not influence the
relationship of the polymorphic variant with type 2 diabetes
risk. In a subgroup analysis, the RBP4 polymorphism was
not significantly associated with vitamin A plasma levels.
Munkhtulga et al. [7] were the first to describe the
relationship between RBP4 genetic variants and type 2
diabetes risk. Genotype frequencies for the −803GA
polymorphism in this Mongolian population were approx-
imately equal to the genotype frequencies in our white
population. Similarly to our results, the −803A allele was
associated with increased risk of type 2 diabetes. However,
a dominant mode of inheritance was found as opposed to
our finding of a recessive pattern. The difference in race
and differences in exposure to environmental factors
between the populations may explain the discrepancy. In
two separate studies, white carriers of an RBP4 haplotype
had a significantly increased risk of type 2 diabetes [14,
15]. However, the individual RBP4 polymorphisms were
not related to risk of type 2 diabetes. In both studies, the
haplotype associated with increased risk contained the
−803G allele. This seems to contradict our findings, but
the associated haplotype was not determined by the
−803GA variant. The majority of the haplotypes found
(four out of five) contained the −803G allele and were not
associated with an increased risk, which makes it unlikely
that the G allele contributed to the observed effect. The
relatively small sample size of the study by Craig et al. [14]
and the presence of considerably younger controls than
cases in the study by Kovacs et al. [15] might have hidden
the effect of the individual polymorphism. Hence, the
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Fig. 1 Diabetes-free survival rate according to RBP4 −803GA
genotypes. Solid line, GG; dotted line, GA; dashed line, AA
Table 2 HRs for type 2 diabetes according to RBP4 −803GA genotype
Genotype HR1
a 95% CI p value HR2
b 95% CI p value
−803GG/GA 1.0 1.0
−803AA 1.83 1.26–2.66 0.001 1.81 1.25–2.64 0.002
aAdjusted for year of birth and sex
bAdjusted for year of birth, sex and BMI
1426 Diabetologia (2008) 51:1423–1428findings in our large follow-up study do not necessarily
contradict the two previous case–control studies: multiple
RBP4 variants may affect type 2 diabetes risk, including
variants captured by the haplotypes described in the other
references [14, 15], or by the −803GA polymorphism itself.
Since RBP4 is the only known retinol transport protein,
a retinol-dependent mechanism underlying its effect on type
2 diabetes risk seems a reasonable assumption. Within
tissues, retinol is activated to retinoic acid isomers, which
have a wide array of pleiotropic effects through interaction
with retinoid acid X receptors (RXRs) and retinoic acid
receptors [16], regulating transcription of over 300 target
genes [17]. Consistent with a retinol-dependent mechanism
Yang et al. [3] found that RBP4 increased PEPCK
expression in mouse liver and cultured hepatocytes. PEPCK
is a gluconeogenic enzyme and retinoids regulate its
transcription [18]. All retinoids in the body originate from
the diet [19, 20]. We did not find an association of retinol
intake with type 2 diabetes risk. Conflicting results
concerning this relationship have been published [21–25].
We did not observe interaction between retinol intake and
the RBP4 polymorphism on type 2 diabetes risk, nor did we
find an association of the polymorphism with vitamin A
plasma levels. However, since the effect on type 2 diabetes
risk was confined to the −803A homozygotes and the
analyses with vitamin A plasma levels contained only a
small number of −803A homozygotes (n=10), these results
should be interpreted with caution. Compared with the
other genotypes, the −803A homozygotes had a slightly
higher mean plasma vitamin A level, although not signi-
ficant. Therefore we cannot exclude the possibility that a
retinol-dependent mechanism underlies the effect on type 2
diabetes risk. Moreover, the relationship between metabo-
lites of retinol and insulin sensitivity may be complex, as
some retinoic acids are thought to cause insulin resistance
[26, 27], whereas others seem protective through RXR–
peroxisome proliferator-activated receptor γ-activated path-
ways [28]. Based on our results we cannot exclude that
RBP4 alters the amount of specific retinoic acid isomers
locally or systemically. However, a number of retinol-
independent mechanisms may operate: RBP4 may increase
type 2 diabetes risk by binding of cell surface receptors [29,
30], such as megalin and Stra6. Recently, it was shown that
RBP4 can directly affect insulin signalling by blocking the
insulin-stimulated phosphorylation of IRS-1 [31]. Further-
more, RBP4 may modulate transthyretin function. Trans-
thyretin was recently shown to be involved in beta cell
stimulus–secretion coupling [32, 33].
The relationship between genetic variation in the RBP4
gene and type 2 diabetes had not previously been
investigated prospectively at a population-based level. We
identified all incident cases of type 2 diabetes in this our
large population-based study during a long period of
follow-up. The availability of data on retinol intake in all
individuals and vitamin A plasma levels in a subgroup
allowed us to investigate potential associations and inter-
actions between RBP4 genetic variation and these param-
eters. To the best of our knowledge, this is the first study to
examine this interaction.
In a previous study −803GA polymorphism was identi-
fied as a functional variant that affects HNF1α binding,
RBP4 transcription efficiency and RBP4 plasma levels.
Unfortunately, RBP4 plasma levels in the Rotterdam Study
are not available because of limitations in sample availabil-
ity and lack of a readily available and reliable method to
measure these levels in large populations and people with
insulin resistance [34]. Kovacs et al. did not find an effect
of the −803GA polymorphism on serum RBP4 levels in a
case–control study [15]. Future studies are needed to obtain
insight in the relationship between RBP4 serum levels and
the genetic variation in the RBP4 gene.
In conclusion, we have shown prospectively that a promoter
polymorphism in the RBP4 gene is associated with increased
risk of type 2 diabetes in the Rotterdam population. Along
with previous functional data our finding increases the
confidence that the promoter polymorphism is a causal
variant. Dietary intake of retinol did not influence type 2
diabetes risk or the association of the RBP4 polymorphism
with type 2 diabetes risk. Moreover, the RBP4 polymorphism
was not significantly associated with circulating vitamin A
levels. However, we could not exclude a retinol-dependent
mechanism underlying the association with type 2 diabetes.
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Table 3 Plasma vitamin A levels according to RBP4 −803GA
genotype
−803GA n Vitamin A (μmol/l)
GG 256 1.61±0.02
GA 129 1.59±0.03
AA 10 1.64±0.09
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